carbogen has been researched along with Cancer of Larynx in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bussink, J; De Bree, R; Doornaert, PA; Hoogsteen, IJ; Kaanders, JH; Langendijk, JA; Oosterwijk, E; Rademakers, SE; Rijken, PF; Takes, R; Terhaard, CH; van den Ende, P; van der Kogel, AJ | 1 |
| Betts, GN; Buffa, FM; Denley, H; Eustace, A; Harris, AL; Homer, JJ; Hoskin, PJ; Irlam, JJ; Kaanders, JH; Mani, N; Miller, CJ; Rojas, AM; Span, PN; Taylor, J; West, CM | 1 |
| Bussink, J; Doornaert, PA; Hoogsteen, IJ; Kaanders, JH; Langendijk, JA; Rademakers, SE; Rijken, PF; Terhaard, CH; van den Ende, P; van der Kogel, AJ | 1 |
| Bijl, HP; de Jong, MA; Doornaert, PA; Janssens, GO; Kaanders, JH; Span, PN; Terhaard, CH; van Bockel, LW; van den Broek, GB; van den Ende, P; Verbist, BM | 1 |
| Bijl, HP; Bussink, J; Chin, A; de Bree, R; Doornaert, PA; Hoogsteen, IJ; Janssens, GO; Kaanders, JH; Rademakers, SE; Span, PN; Takes, RP; Terhaard, CH; van den Ende, P | 1 |
| de Jong, MA; Doornaert, PA; Janssens, GO; Kaanders, JH; Langendijk, JA; Span, PN; Takes, RP; Terhaard, CH; van den Ende, P | 1 |
| Bijl, HP; Chin, A; Doornaert, PA; Janssens, GO; Kaanders, JH; Pop, LA; Terhaard, CH; van den Ende, P | 1 |
| Peters, L; Rischin, D | 1 |
| Bijl, HP; Bussink, J; Chin, A; de Bree, R; Doornaert, PA; Hoogsteen, IJ; Janssens, GO; Kaanders, JH; Marres, HA; Rademakers, SE; Span, PN; Terhaard, CH; van den Ende, P; van der Kogel, AJ | 1 |
| Kaanders, JH; Marres, HA; Pop, LA; van Daal, WA; van der Kogel, AJ; van der Maazen, RW | 1 |
| Kaanders, JH; Liefers, J; Marres, HA; Pop, LA; van Daal, WA; van den Hoogen, FJ; van der Kogel, AJ | 1 |
| Bussink, J; Hodgkiss, RJ; Kaanders, JH; Marres, HA; Peters, JP; Rijken, PF; van der Kogel, AJ | 1 |
7 trial(s) available for carbogen and Cancer of Larynx
| Article | Year |
|---|---|
Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carbonic Anhydrase IX; Carbonic Anhydrases; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Niacinamide; Nitroimidazoles; Oxygen; Prognosis; Treatment Outcome | 2013 |
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Topics: Carbon Dioxide; Cell Hypoxia; Female; Gene Expression Regulation, Neoplastic; Humans; Laryngeal Neoplasms; Male; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2013 |
Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oxygen; Prognosis; Radiation-Sensitizing Agents; Vitamin B Complex | 2015 |
Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Biomarkers; Carbon Dioxide; Female; Hemoglobins; Humans; Hypoxia; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Oxygen; Prognosis; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome | 2014 |
Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Oxygen; Quality of Life; Radiation-Sensitizing Agents; Societies, Medical; Surveys and Questionnaires | 2016 |
Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Carbon Dioxide; Carcinoma, Squamous Cell; Deglutition Disorders; Female; Humans; Intubation, Gastrointestinal; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Netherlands; Niacinamide; Oxygen; Patient Compliance; Radiation-Sensitizing Agents; Radiodermatitis; Stomatitis; Vitamin B Complex | 2012 |
Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbon Dioxide; Carcinoma, Squamous Cell; Chi-Square Distribution; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Oxygen; Patient Selection; Proportional Hazards Models; Radiation-Sensitizing Agents; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United Kingdom; Vitamin B Complex | 2012 |
5 other study(ies) available for carbogen and Cancer of Larynx
| Article | Year |
|---|---|
Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
Topics: Carbon Dioxide; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Oxygen; Prognosis; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Elusive goal of targeting tumor hypoxia for therapeutic gain.
Topics: Carbon Dioxide; Carcinoma, Squamous Cell; Female; Humans; Laryngeal Neoplasms; Male; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Vitamin B Complex | 2012 |
Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Mucoepidermoid; Carcinoma, Squamous Cell; Feasibility Studies; Female; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Niacinamide; Oropharyngeal Neoplasms; Oxygen; Palliative Care; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1995 |
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Topics: Actuarial Analysis; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma; Cell Division; Cell Hypoxia; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oxygen; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 1998 |
Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide.
Topics: Animals; Benzimidazoles; Blood Vessels; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Division; Endothelium, Vascular; Humans; Hypoxia; Laryngeal Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Theophylline; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |